Biotech Values

[aslan2772]

SRDX's vitreal implant could make stent royalties look like small potatoes without going anywhere near a $20K price tag, especially if SRDX can garner double-digit royalties. Drug cost aside, manufacturing this simple device must be quite inexpensive. It sounds to me like health cost savings could be an added bennefit if this device pans out.